Amnestix, Inc

Founded in 2006, Amnestix focuses on novel therapeutics for improving memory associated with a variety of diseases. Amnestix was created from pioneering discoveries in neurogenomics and memory and cognitive function by Dr. Dietrich Stephan and Dr. Matthew Huentelman at the Translational Genomics Research Institutein Phoenix, Arizona. The company is headquartered in Burlingame, California. The seed funding for Amnestix was provided by the Brain Trust Accelerator Fund, LP managed by John Reher.